These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34954239)

  • 1. Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain).
    Vives N; Binefa G; Vidal C; Milà N; Muñoz R; Guardiola V; Rial O; Garcia M
    Prev Med; 2022 Feb; 155():106929. PubMed ID: 34954239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic.
    Kortlever TL; de Jonge L; Wisse PHA; Seriese I; Otto-Terlouw P; van Leerdam ME; Spaander MCW; Dekker E; Lansdorp-Vogelaar I
    Prev Med; 2021 Oct; 151():106643. PubMed ID: 34217421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population.
    Lee JK; Lam AY; Jensen CD; Marks AR; Badalov J; Layefsky E; Kao K; Ho NJ; Schottinger JE; Ghai NR; Carlson CM; Halm EA; Green B; Li D; Corley DA; Levin TR
    Gastroenterology; 2022 Sep; 163(3):723-731.e6. PubMed ID: 35580655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A delay in the diagnosis of colorectal cancer screened by fecal immunochemical tests during the COVID-19 pandemic: a longitudinal cohort study.
    Ishibashi F; Shida D; Suzuki S; Nagai M; Mochida K; Morishita T
    Int J Colorectal Dis; 2022 Dec; 37(12):2543-2546. PubMed ID: 36383225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
    Pilonis ND; Bugajski M; Wieszczy P; Rupinski M; Pisera M; Pawlak E; Regula J; Kaminski MF
    Gastroenterology; 2021 Mar; 160(4):1097-1105. PubMed ID: 33307024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of delayed screening invitations on screen-detected and interval cancers in the Dutch colorectal cancer screening programme: individual-level data analysis.
    Toes-Zoutendijk E; de Jonge L; van Iersel CA; Spaander MCW; van Vuuren AJ; van Kemenade F; Ramakers CR; Dekker E; Nagetaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Gut; 2023 Jul; 72(7):1319-1325. PubMed ID: 37076272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study.
    Sadeghi A; Asadzadeh Aghdaei H; Khalafi MA; Nazemalhosseini-Mojarad E; Ketabi Moghadam P; Sohrabi MR
    BMC Cancer; 2023 Jul; 23(1):627. PubMed ID: 37407931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the COVID-19 Pandemic on the Diagnosis of Colorectal Cancer within a Population-Based Organized Screening Program.
    Cubiella J; Calderón-Cruz B; Almazán R; Gómez-Amorín Á
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region.
    Chiu HM; Su CW; Hsu WF; Jen GH; Hsu CY; Chen SL; Chen HH
    Prev Med; 2021 Oct; 151():106622. PubMed ID: 34044024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
    Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: a Systematic Review.
    Mazidimoradi A; Tiznobaik A; Salehiniya H
    J Gastrointest Cancer; 2022 Sep; 53(3):730-744. PubMed ID: 34406626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationwide participation in FIT-based colorectal cancer screening in Denmark during the COVID-19 pandemic: An observational study.
    Olesen TB; Jensen H; Møller H; Jensen JW; Andersen B; Rasmussen M
    Elife; 2023 Jan; 12():. PubMed ID: 36695411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the impacts of COVID-19 pandemic on the quality of population-based colorectal cancer screening.
    Jen GH; Yen AM; Hsu CY; Chiu HM; Chen SL; Chen TH
    Prev Med; 2021 Oct; 151():106597. PubMed ID: 34217416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The COVID-19 Pandemic: Identifying Adaptive Solutions for Colorectal Cancer Screening in Underserved Communities.
    Nodora JN; Gupta S; Howard N; Motadel K; Propst T; Rodriguez J; Schultz J; Velasquez S; Castañeda SF; Rabin B; Martínez ME
    J Natl Cancer Inst; 2021 Aug; 113(8):962-968. PubMed ID: 32780851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic.
    de Jonge L; van de Schootbrugge-Vandermeer HJ; Breekveldt ECH; Spaander MCW; van Vuuren HJ; van Kemenade FJ; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    PLoS One; 2022; 17(6):e0270223. PubMed ID: 35749423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of colorectal cancer screening participation in remote northern Canada: A retrospective cohort study.
    Smith HA; Scarffe AD; Brunet N; Champion C; Kandola K; Tessier A; Boushey R; Kuziemsky C
    World J Gastroenterol; 2020 Dec; 26(48):7652-7663. PubMed ID: 33505142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.